Success Stories: Company-Petitioned EB-1B Approved for Researcher in Minnesota in the Field of Pharmaceutical Sciences
Client’s Testimonial:
“I have noticed that my I-140 application has been approved last night. Thanks for your help.”
On February 20th, 2018, we received another EB-1B (Outstanding Professors and Researchers) approval for a Researcher in the Field of Pharmaceutical Sciences (Approval Notice).
General Field: Pharmaceutical Sciences
Position at the Time of Case Filing: Researcher
Country of Origin: India
State of Residence at the Time of Filing: Minnesota
Approval Notice Date: February 20th, 2018
Processing Time: 6 Days (Premium Processing Requested)
Case Summary:
Exactly 6 days after North America Immigration Law Group (NAILG) filed an EB-1B (Outstanding Professors and Researchers) petition for a researcher from India, the USCIS approved it. The reason it only took them 6 days to adjudicate our client’s petition is because he filed it with Premium Processing.
Qualifying for EB-1B:
EB-1B is a subcategory of priority worker. To qualify for this I-140 category, our client had to be internationally recognized as an outstanding researcher in the field of pharmaceutical sciences. He also had more than three years of research experience along with ongoing employment from an American employer—a well-known university.
Building a strong EB-1B case:
The EB1B petition we put together for our client was customized according to his skills and strengths. For instance, we noted his Ph.D. in Pharmaceutical Sciences and described his work on the development of polymeric nanomaterials for gene delivery, DNA vaccine development, and bioanalytical methods. We also listed the 492 times his 18 publications were cited as well as the 59 times he had judged the work of his peers.
To further prove to the USCIS that our client is a force to be reckoned with, we asked him to enlist the help of other influential scientists in the field. He reached out to them and obtained recommendation letters, all four of which contained important information on the significance of his research to not just the United States but the field as a whole. This is what one of our client’s recommenders noted in his letter of support: “[Client] stands at the forefront of research essential to advancing pharmaceutical science, particularly in cancer treatments and central nervous system disorders.”
With a success rate of over 10,000 cases, we undoubtedly have unprecedented insight into what the USCIS is looking for in I-140 petitions. The approval of this EB1B case is yet another example of our sterling record of helping our clients get one step closer to their green card. We thank our client for placing his trust in us, and we wish him the best as he continues to progress the field of pharmaceutical sciences.